Literature DB >> 26710982

Constitutive active/androstane receptor, peroxisome proliferator-activated receptor α, and cytotoxicity are involved in oxadiazon-induced liver tumor development in mice.

Kazunori Kuwata1, Kaoru Inoue2, Ryohei Ichimura2, Miwa Takahashi2, Yukio Kodama3, Midori Yoshida4.   

Abstract

Oxadiazon (OX) is a protoporphyrinogen oxidase-inhibiting herbicide that induces porphyria and liver tumors in rodents. Although porphyria is generally considered to be a risk factor for liver tumor development, the mechanisms through which OX mediates tumor development are unclear. Therefore, in this study, we investigated the mechanisms of tumor development by focusing on constitutive active/androstane receptor (CAR), which is essential for the development of tumors in response to several chemicals. After 1, 4, or 13 weeks of dietary treatment with 1000 ppm OX, hepatic Cyp2b10 expression was induced in wild-type (WT) mice. However, this effect was blocked in CAR-knockout (CARKO) mice. Hepatic Cyp4a10 expression, indicative of peroxisome proliferator-activated receptor α (PPARα) activation, and cytotoxic changes in hepatocytes were also observed in both groups of mice. After initiation by diethylnitrosamine, 26-week treatment with OX resulted in an increase in proliferative lesions, including foci and adenomas, in both genotypes, and the incidence and multiplicity of proliferative lesions in CARKO mice were higher than those in control mice but lower than those in WT mice. These results suggested that CAR, PPARα activation, and cytotoxicity were involved in the development of liver tumors. Moreover, porphyrin was not apparently involved in OX-induced tumor development.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CAR; Liver tumorigenesis; Mice; Oxadiazon; Porphyrin

Mesh:

Substances:

Year:  2015        PMID: 26710982     DOI: 10.1016/j.fct.2015.12.017

Source DB:  PubMed          Journal:  Food Chem Toxicol        ISSN: 0278-6915            Impact factor:   6.023


  2 in total

1.  Systems Pharmacology-Based Identification of Mechanisms of Action of Bolbostemma paniculatum for the Treatment of Hepatocellular Carcinoma.

Authors:  Lan-Lan Wang; Chen Liao; Xiao-Qiang Li; Rong Dai; Qing-Wei Ren; Hai-Long Shi; Xiao-Ping Wang; Xue-Song Feng; Xu Chao
Journal:  Med Sci Monit       Date:  2021-01-13

2.  Identification of novel lipid biomarkers in xmrk- and Myc-induced models of hepatocellular carcinoma in zebrafish.

Authors:  Jerry D Monroe; Daniel Fraher; Xiaoqian Huang; Natalie A Mellett; Peter J Meikle; Andrew J Sinclair; Seth T Lirette; Nita J Maihle; Zhiyuan Gong; Yann Gibert
Journal:  Cancer Metab       Date:  2022-04-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.